- Takeda, Anderson Cancer Center accelerate cell therapy
- Stone Capital, Biosyngen to set up $50M biopharma investment fund
- OSE Immunotherapeutics inks licensing deal with Chong Kun Dang Pharma
- Spectrum Therapeutics focuses on Real World Evidence research
- GE Healthcare, Akeso Pharma to expedite novel therapy manufacturing in China
- US$2 billion Investments Programme to Support Growth of Green Finance in Singapore
- China approves Alzheimer's drug
- BC Platforms establishes new entity in Singapore
- Kayentis opens Japanese subsidiary
- NUS researchers identify new Alzheimer’s biomarker
- Icon Group expands footprint in Asia Pacific
- Lucence, MEDx to co-develop cutting-edge cancer care tests
- Roxadustat Phase III study shows positive efficacy in patients with anaemia from CKD
- Takeda unveils new dengue vaccine manufacturing plant in Germany
-
Singapore | 04 July 2019 | News
Latest technologies to transform healthcare
A new consortium led by the Institute for Health Innovation and Technology (iHealthtech) at NUS will tap on th...Read more
Europe | 05 November 2019 | Influencers
TPP Commits To Transform The Delivery of Health and Care Globally
Nov Special Interview - Malaysia. TPP is a healthcare technology company, dedicated to delivering world...Read more
-
Korea | 12 November 2019 | News
OSE Immunotherapeutics inks licensing deal with Chong Kun Dang Pharma
French biotech company OSE Immunotherapeutics has announced a new licensing deal with South Korea based C...Read more
-
Japan | 12 November 2019 | News
Takeda, Anderson Cancer Center accelerate cell therapy
University of Texas MD Anderson Cancer Center (The University of Texas MD Anderson Cancer Center) an...Read more
-
Middle East countries | 16 July 2019 | News
Filterlex Medical raises $3M in Series A Financing
Filterlex Medical is a medical device start-up company based in Israel, developing an innovative embolic ...Read more
-
Thailand | 30 July 2019 | News
Thai startups to capture a major chunk of healthcare market
The medical device market in ASEAN is predicted to be worth US$8.5 billion by 2021, and Thai entrepreneurs wan...Read more
Needs much more for world without diabetes
Diabetes is on the rise across the globe as reported in the most recent 8th edition of the International Diabetes Federation (IDF) Diabetes Atlas 2017. As Diabetes is a lifestyle disease, it can be prevented by adopting appropriate lifestyle. This is what the evidence from studies conducted in the USA, Finland, China, India and Japan have proved. However, the pharma industry has been investing on R&D and launching new products but needs much more. From January 2019 to October 31, 2019, the US FDA has approved three products for type 2 diabetes (two drugs Rybelsus and Victoza from Novo Nordisk and one drug – Farxiga from AstraZeneca).
